COMMUNIQUÉS West-GlobeNewswire

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs [...]
Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease
11/06/2026
Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving [...]
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
11/06/2026
Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ). 1 HCP survey data suggests only around [...]
Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026
11/06/2026
NEW YORK, 11 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
11/06/2026
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, [...]
Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
11/06/2026
Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at WCN 2026 Pronounced [...]
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
11/06/2026
Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone 1 Nearly one in three patients with stage III colon [...]
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
11/06/2026
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax [...]
Glass House Brands Announces the Filing of Shelf Prospectus and At-The-Market Distribution Program
11/06/2026
LONG BEACH, Calif. and TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“ Glass House ” or the “ Company ”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that [...]
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
11/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
11/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Tilray Medical Allemagne lance ARX™, une nouvelle marque de cannabis médicinal haut de gamme cultivé en Allemagne
11/06/2026
La nouvelle marque associe des variétés éprouvées, l’expertise allemande en matière de culture et des normes de qualité rigoureuses au service des patients et des professionnels de santé dans toute l’Allemagne [...]
CARPL.ai Partners with Enlitic to Accelerate AI Validation for Imaging Customers
11/06/2026
CUPERTINO, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- CARPL.ai, the world's largest radiology AI marketplace and enterprise platform, today announced a partnership with Enlitic, to give imaging customers a stronger [...]
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
10/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
10/06/2026
POMPANO BEACH, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
10/06/2026
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today [...]
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
10/06/2026
APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
10/06/2026
ZUG, Switzerland, June 10, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' [...]
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch
10/06/2026
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch Mont-Saint-Guibert, Belgium – June 10, 2026, 10:30 pm CET / 04:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “ [...]

Pages